Advertisement

Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery

  • Yoshihiro Miyasaka
  • Takao Ohtsuka
  • Ryuichiro Kimura
  • Ryota Matsuda
  • Yasuhisa Mori
  • Kohei Nakata
  • Daisuke Kakihara
  • Nao Fujimori
  • Takamasa Ohno
  • Yoshinao Oda
  • Masafumi NakamuraEmail author
Pancreatic Tumors
  • 108 Downloads

Abstract

Background

Accumulation of evidence suggests that neoadjuvant chemotherapy improves the outcomes of borderline resectable pancreatic cancer (BRPC). Gemcitabine plus nab-paclitaxel (GnP) has been widely accepted as systemic chemotherapy for unresectable pancreatic cancer and reportedly results in remarkable tumor shrinkage. This study was performed to evaluate the safety and efficacy of neoadjuvant chemotherapy using neoadjuvant GnP for BRPC.

Methods

The medical records of 57 patients who underwent treatment of BRPC from 2010 to 2017 were retrospectively reviewed. The patient characteristics and short- and intermediate-term outcomes were compared between the GnP and upfront surgery (UFS) groups.

Results

The GnP group comprised 31 patients and the UFS group comprised 26 patients. The patient characteristics were comparable with the exception of a higher prevalence of arterial involvement in the GnP group. Twenty-seven of the 31 patients (87%) in the GnP group and all 26 patients in the UFS group underwent resection. The GnP group showed a significantly shorter operation time (429 vs. 509.5 min, p = 0.0068), less blood loss (760 vs. 1324 ml, p = 0.0115), and a higher R0 resection rate (100% vs. 77%, p = 0.0100) than the UFS group. Postoperative complications and hospital stay were comparable between the two groups, and no treatment-related mortality occurred in either group. Both the disease-free survival and overall survival times were significantly longer in the GnP group (p = 0.0018 and p = 0.0024, respectively).

Conclusions

Neoadjuvant GnP is a safe and effective treatment strategy for BRPC. It potentially improves patients’ prognosis and facilitates surgical procedures.

Notes

Acknowledgment

This study was supported by Grants-in-Aid for Scientific Research (KAKENHI; #16K10601).

Disclosures

Yoshihiro Miyasaka, Takao Ohtsuka, Ryuichiro Kimura, Ryota Matsuda, Yasuhisa Mori, Kohei Nakata, Daisuke Kakihara, Nao Fujimori, Takamasa Ohno, Yoshinao Oda, and Masafumi Nakamura declare no conflicts of interest related to this article.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.CrossRefGoogle Scholar
  2. 2.
    Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57.CrossRefGoogle Scholar
  3. 3.
    Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.CrossRefGoogle Scholar
  4. 4.
    Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833–46; discussion 46–48.CrossRefGoogle Scholar
  5. 5.
    Kato H, Usui M, Isaji S, et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20:601–10.CrossRefGoogle Scholar
  6. 6.
    Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42:1004–10.CrossRefGoogle Scholar
  7. 7.
    Hirono S, Kawai M, Okada KI, et al. Treatment strategy for borderline resectable pancreatic cancer with radiographic artery involvement. Pancreas. 2016;45:1438–46.CrossRefGoogle Scholar
  8. 8.
    Lee JH, Kang CM, Bang SM, et al. The role of neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic cancer with isolated venous vascular involvement. Medicine (Baltimore). 2015;94:e1233.CrossRefGoogle Scholar
  9. 9.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.CrossRefGoogle Scholar
  10. 10.
    Ueno H, Ikeda M, Ueno M, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016;77:595–603.CrossRefGoogle Scholar
  11. 11.
    Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1028–61.CrossRefGoogle Scholar
  12. 12.
    Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual 7th Edition. New York: Springer; 2010.Google Scholar
  13. 13.
    Tang K, Lu W, Qin W, Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16:28–37.CrossRefGoogle Scholar
  14. 14.
    Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105:946–58.CrossRefGoogle Scholar
  15. 15.
    Muranaka T, Kuwatani M, Komatsu Y, et al. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017;8:566–71.CrossRefGoogle Scholar
  16. 16.
    Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109:926–33.CrossRefGoogle Scholar
  17. 17.
    Cooper AB, Parmar AD, Riall TS, et al. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? J Gastrointest Surg. 2015;19:80–6; discussion 86–87.CrossRefGoogle Scholar
  18. 18.
    Denbo JW, Bruno ML, Cloyd JM, et al. Preoperative chemoradiation for pancreatic adenocarcinoma does not increase 90-day postoperative morbidity or mortality. J Gastrointest Surg. 2016;20:1975–85.CrossRefGoogle Scholar
  19. 19.
    Ielpo B, Duran H, Diaz E, et al. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol. 2016;42:1394–1400.CrossRefGoogle Scholar
  20. 20.
    Fujii T, Yamada S, Murotani K, et al. Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment. Medicine (Baltimore). 2015;94:e1647.CrossRefGoogle Scholar
  21. 21.
    Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268:215–22.CrossRefGoogle Scholar
  22. 22.
    Gnerlich JL, Luka SR, Deshpande AD, et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg. 2012;147:753–60.CrossRefGoogle Scholar
  23. 23.
    Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.CrossRefGoogle Scholar
  24. 24.
    Ielpo B, Caruso R, Duran H, et al. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Surg Oncol. 2017;26:402–10.CrossRefGoogle Scholar
  25. 25.
    Murakami Y, Satoi S, Sho M, et al. National Comprehensive Cancer Network resectability status for pancreatic carcinoma predicts overall survival. World J Surg. 2015;39:2306–14.CrossRefGoogle Scholar
  26. 26.
    Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Yoshihiro Miyasaka
    • 1
  • Takao Ohtsuka
    • 1
  • Ryuichiro Kimura
    • 1
  • Ryota Matsuda
    • 1
    • 2
  • Yasuhisa Mori
    • 1
  • Kohei Nakata
    • 1
  • Daisuke Kakihara
    • 3
  • Nao Fujimori
    • 4
  • Takamasa Ohno
    • 4
  • Yoshinao Oda
    • 2
  • Masafumi Nakamura
    • 1
    Email author
  1. 1.Department of Surgery and Oncology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of Anatomic Pathology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  3. 3.Department of Clinical Radiology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  4. 4.Department of Medicine and Bioregulatory Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations